The CCR4 Antagonist, FLX475, Alters Treg Infiltration & Localization in the Tumor Microenvironment & Improves Clinical Response

Time: 4:15 pm
day: Day One


• Discovering how FLX475 works and its impact on altering Treg infiltration within the tumor microenvironment

• Exploring how FLX475 influences Treg migration and localization, with a focus on strategies to target the tumor microenvironment for improved therapeutic outcomes

• Uncovering the latest clinical trial results and future directions for utilizing FLX475 to enhance clinical responses in cancer treatment